Literature DB >> 15193454

Pharmacology of nuclear receptor-coregulator recognition.

Rajesh S Savkur1, Kelli S Bramlett, David Clawson, Thomas P Burris.   

Abstract

The nuclear receptor (NR) superfamily comprises approximately 50 members that are responsible for regulating a number of physiologic processes in humans, including metabolism, homeostasis, and reproduction. Included in the superfamily are the receptors for steroids, lipophilic vitamins, bile acids, retinoids, and various fatty acids. NRs exert their action as transcription factors that directly bind to the promoters of target genes and regulate their rate of transcription. To modulate transcription, however, NRs must recruit a number of accessory coregulators known as corepressors and coactivators. These coregulators harbor a variety of activities, such as the ability to modify chromatin structure, interact with basal transcriptional machinery, and modify RNA splicing. Recent studies have revealed that the pharmacological characteristics of various NR ligands are regulated by their ability to modulate the coregulator interaction profile of an NR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193454     DOI: 10.1016/S0083-6729(04)68005-8

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  10 in total

1.  SMRTε, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors α and β.

Authors:  Brenda J Mengeling; Michael L Goodson; William Bourguet; Martin L Privalsky
Journal:  Mol Cell Endocrinol       Date:  2012-01-12       Impact factor: 4.102

2.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

3.  A mechanism for pituitary-resistance to thyroid hormone (PRTH) syndrome: a loss in cooperative coactivator contacts by thyroid hormone receptor (TR)beta2.

Authors:  Sangho Lee; Briana M Young; Wei Wan; Ivan H Chan; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2011-05-26

Review 4.  A current structural perspective on PXR and CAR in drug metabolism.

Authors:  Cameron D Buchman; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-05-30       Impact factor: 4.481

5.  Relationship between circadian oscillations of Rev-erbalpha expression and intracellular levels of its ligand, heme.

Authors:  Pamela M Rogers; Ling Ying; Thomas P Burris
Journal:  Biochem Biophys Res Commun       Date:  2008-02-15       Impact factor: 3.575

Review 6.  Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock.

Authors:  Thomas P Burris
Journal:  Mol Endocrinol       Date:  2008-01-24

7.  Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist.

Authors:  Edna Matta-Camacho; Subhashis Banerjee; Travis S Hughes; Laura A Solt; Yongjun Wang; Thomas P Burris; Douglas J Kojetin
Journal:  J Biol Chem       Date:  2014-05-28       Impact factor: 5.157

8.  Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination.

Authors:  Thomas J Berrodin; Ken C N Chang; Barry S Komm; Leonard P Freedman; Sunil Nagpal
Journal:  Mol Endocrinol       Date:  2008-11-26

9.  Corepressor diversification by alternative mRNA splicing is species specific.

Authors:  Martin L Privalsky; Chelsea A Snyder; Michael L Goodson
Journal:  BMC Evol Biol       Date:  2016-10-19       Impact factor: 3.260

10.  Confirmation of high-throughput screening data and novel mechanistic insights into VDR-xenobiotic interactions by orthogonal assays.

Authors:  Debabrata Mahapatra; Jill A Franzosa; Kyle Roell; Melaine Agnes Kuenemann; Keith A Houck; David M Reif; Denis Fourches; Seth W Kullman
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.